Generic bests Botox for migraine: MDs

Share this article:
Topiramate, the generic name for Ortho-McNeil/Janssen-Cilag's Topamax, is the sales leader among drugs approved for chronic migraine. So, it came as no surprise that a Decision Resources survey of neurologists found that the highest percentage of neurologists (55%) and MCO pharmacy directors (40%) rated it the most efficacious current therapy for the condition.
However, neurologists reported being only moderately satisfied with topiramate's accessibility. The drug went generic in 2009, and insurance coverage may vary depending on whether plans have yet to reevaluate tiering and grant it more favorable placement.
Topiramate and onabotulinumtoxinA (Allergan's Botox), which won approval for the indication last October, are the only prophylactic therapies to demonstrate efficacy against chronic migraine in multiple placebo-controlled clinical trials.
Decision Resources expects the Botox approval to spur diagnosis and treatment of the
condition.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?